IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
NCT05365659
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
140
Enrollment
INDUSTRY
Sponsor class
Conditions
B-cell Non-Hodgkin Lymphoma
Diffuse Large B Cell Lymphoma
Follicular Lymphoma
Mantle Cell Lymphoma
B-cell Lymphoma
Interventions
DRUG:
IKS03
Sponsor
Iksuda Therapeutics Ltd.